Related Experiment Video
Updated: Jun 17, 2026
07:51
Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
Published on: March 20, 2026
Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B
Yuto Kaimi1,2, Yuka Takahashi1,3, Mai Takeuchi1
1Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Virchows Archiv : an International Journal of Pathology
|June 16, 2026
Summary
Polatuzumab vedotin (PV) is effective for diffuse large B-cell lymphoma (DLBCL), even with low CD79B expression. CD79B levels did not predict treatment outcomes or relapse risk in DLBCL patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Polatuzumab vedotin (PV) is an antibody-drug conjugate targeting CD79B for diffuse large B-cell lymphoma (DLBCL).
- The clinical significance of CD79B expression and its modulation by PV therapy in DLBCL is not fully understood.
Purpose of the Study:
- To investigate the association between CD79B expression levels and the efficacy of PV-containing therapy in DLBCL.
- To assess the frequency of CD79B expression loss or decrease following PV treatment.
Main Methods:
- Immunohistochemical analysis of CD79B expression using H-score in 91 DLBCL patients before PV therapy.
- Evaluation of post-treatment changes in CD79B expression in recurrent tumor biopsies.
Main Results:
- Low CD79B expression was found in 16% of patients; this did not correlate with relapsed/refractory (R/R) DLBCL incidence.
- 60% of patients with low CD79B expression achieved complete response to PV therapy.
- 13% of patients showed loss or decrease of CD79B expression upon recurrence after PV therapy.
Conclusions:
- CD79B expression level is not a significant predictor of PV therapy efficacy in DLBCL.
- PV-containing regimens demonstrate effectiveness even in DLBCL cases with initially low CD79B expression.
